Inovio is going after the 'impossible tumor' left in the dust of new cancer meds

Inovio is going after the 'impossible tumor' left in the dust of new cancer meds

Source: 
Fierce Biotech
snippet: 

Patients with difficult cancers have seen a massive influx of new treatment options and hope for prolonged survival in recent years—except for those with the aggressive brain cancer glioblastoma.

Inovio is hoping to change that with a new DNA medicine combination of INO-5401, INO-9012 and Regeneron-Sanofi’s PD-1 inhibitor Libtayo. The Plymouth Meeting, Pennsylvania-based biotech is conducting a phase 1 clinical trial called GBM-001 that will provide early data in a quest to extend the lives of newly-diagnosed patients beyond the three to five years that is currently the norm.